Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aprea Therapeutics, Inc. (APRE)

3.82   0.02 (0.53%) 05-31 13:12
Open: 3.79 Pre. Close: 3.8
High: 3.8999 Low: 3.76
Volume: 11,527 Market Cap: 14(M)

Technical analysis

as of: 2023-05-31 12:46:11 PM
Stoxline posted a STRONG BUY today, same as yesterday. Upward movement continues.
Target: Six months: 4.89     One year: 5.71
Support: Support1: 3.65    Support2: 3.32
Resistance: Resistance1: 4.18    Resistance2: 4.89
Pivot: 3.76
Moving Average: MA(5): 3.66     MA(20): 3.79
MA(100): 5.85     MA(250): 10.95
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 49     %D(3): 39.1
RSI: RSI(14): 49.3
52-week: High: 25.79  Low: 0.47
Average Vol(K): 3-Month: 13 (K)  10-Days: 13 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ APRE ] has closed below upper band by 32.6%. Bollinger Bands are 81% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 57 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.81 - 3.83 3.83 - 3.85
Low: 3.31 - 3.33 3.33 - 3.36
Close: 3.76 - 3.8 3.8 - 3.84

Company Description

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Headline News

Tue, 30 May 2023
Aprea Therapeutics to Present at BIO International Convention - GlobeNewswire

Wed, 17 May 2023
HC Wainwright & Co. Reiterates Aprea Therapeutics (APRE) Buy ... - Nasdaq

Mon, 15 May 2023
North American Morning Briefing : Hopes Build for -3- -

Mon, 15 May 2023
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations - Yahoo Finance

Mon, 08 May 2023
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board - GlobeNewswire

Thu, 30 Mar 2023
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 ... - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 4 (M)
Shares Float 2 (M)
% Held by Insiders 16 (%)
% Held by Institutions 14.5 (%)
Shares Short 36 (K)
Shares Short P.Month 20 (K)

Stock Financials

EPS -71.24
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.09
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) -282.3
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -9.1
Qtrly Earnings Growth 0
Operating Cash Flow -22 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.06
PEG Ratio 0
Price to Book value 0.54
Price to Sales 0
Price to Cash Flow -0.64

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.